ESMO 2024: Scientific Progress in Advanced and Hard-to-Treat Cancer
During the upcoming annual meeting of the European Society for Medical Oncology (ESMO), being held in Barcelona, September 13-17, 2024, expect presentations to include new data on advances in the treatment of hard-to-treat cancers using approved and investigational agents, including enfortumab vedotin (Padcev™; Astellas/Pfizer/Seagen), Zolbetuximab (previously known as IMAB362), Enzalutamide (Xtandi®; Astellas/Pfizer) and various pipeline products.
Bristol Myers Squibb Acquires Orum Therapeutics’ ORM-6151 Program
Bristol Myers Squibb (BMS) has acquired Orum Therapeutics’ ORM-6151 program, a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader that has received the FDA’s clearance for Phase 1 for the treatment of patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes.[1]
Datopotamab Deruxtecan + Durvalumab Shows Robust and Durable Tumor Responses in First-Line Treatment of...
Updated results from the BEGONIA phase 1b/2 trial for the cohort of patients treated with datopotamab deruxtecan + durvalumab (Imfinzi®; AstraZeneca; Arm 7) showed that the treatment combination demonstrated durable tumor responses without new safety signals in patients with previously untreated advanced or metastatic triple negative breast cancer (mTNBC) with six months additional follow-up from the previous data cut-off.
ZB131 ADC Induce Potent Anti-tumor Activity CSP-expressing Tumors
Cancer-specific plectin (CSP), a pro-tumorigenic protein selectively expressed on the cell surface of major cancers, is a potentially promising target for the development of novel antibody-drug conjugates (ADC).
European Medicines Agency Validates Marketing Authorization Application for Trastuzumab Duocarmazine
The European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for Byondis’ investigational next generation anti-HER2 antibody-drug conjugate (ADC) trastuzumab duocarmazine* in patients...
